97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti –PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

ConclusionAs demonstrated by the numerically higher ORR, 12-month PFS, and OS, the efficacy of cemiplimab in advanced CSCC may be greater when used as 1LT, supporting its early use for patients with advanced CSCC. Table: 97P Therapeutic setting, number of regimens and type of systemic therapies in pts with PSTPts with PST (N  = 65)Therapeutic setting, n (%)Metastatic disease22 (33.8)Adjuvant10 (15.4)Neoadjuvant4 (6.2)Chemotherapy with concurrent radiation35 (53.8)Other8 (12.3)Number of regimens at baseline, median (range)1 (1–4)Type of PST, n (%)Antineoplastic agents65 (100.0)Platinum compounds46 (70.8)Monoclonal antibodies18 (27.7)Pyrimidine analogues15 (23.1)Taxanes15 (23.1)Protein kinase inhibitors4 (6.2)Combinations of antineoplastic agents3 (4.6)Folic acid analogues1 (1.5)Other antineoplastic agents1 (1.5)Corticosteroids for systemic use1 (1.5)Glucocorticoids1 (1.5)Clinical trial identificationNCT02760498.Editorial acknowledgementMedical writing support under the direction of the authors was provided by Kate Carolan, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication Practice guidelines.Legal entity responsible for the studyRegeneron Pharmaceutical, Inc. and Sanofi.FundingRegeneron Pharmaceutical, Inc. and Sanofi.DisclosureD. Rischin: Research grant / Funding (institution), Non-remunerated activity/ies: Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution): Roche; Research grant / F...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research